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Abstract
Background: Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin) is a member of the
inhibitor of apoptosis protein (IAP) family, which plays an important role in the occurrence and progression of cancer.
Recently, a polymorphism in the promoter of BIRC5, -31C/G (rs9904341), was shown to influence BIRC5 expression.
Methods: We examined whether the -31C/G was related to the risk of developing nasopharyngeal carcinoma (NPC) in a
case-control population from Guangxi province in southern China, which consists of 855 patients with NPC and 1036
controls. This polymorphism was genotyped by TaqMan assay. The genetic associations with the occurrence and
progression of NPC were estimated by logistic regression.
Results: We observed a statistically significant increased occurrence of NPC associated with the CC genotype (odds ratio
[OR], 1.40; 95% confidence interval [CI], 1.13–1.73; P=0.0020) compared with the genotypes containing G allele (CG + GG
genotype). However, no significant association was observed for the -31C/G with the severity of NPC (as measured by
tumor-node-metastasis staging system).
Conclusion: Our findings suggest that the functional polymorphism -31C/G in the promoter of BIRC5 gene may play a role
in mediating the susceptibility to NPC among Chinese.
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Introduction
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy
rarely seen in most regions of the world but is particularly
prevalent among populations from Southeast Asia. [1] Numerous
environmental factors have been reported to confer the risk of
developing NPC, including infection with the Epstein-Barr virus
(EBV), long-term cigarette smoking, occupational exposure to
formaldehyde, and various dietary factors. [2] Genetic factors may
also contribute to the marked racial and geographic differences in
NPC incidence, in that genetic polymorphisms of genes involving
in different steps of carcinogenesis have been implicated in
susceptibility to NPC. [3–14] The identification of susceptibility
genes contributing to NPC would help to clarify pathogenesis of
this malignancy and to predict individual and population risks of
occurrence and progression of NPC.
It’s well known that the apoptosis plays an important role in the
development of cancers. [15] Baculoviral inhibitor of apoptosis
repeat-containing 5 (BIRC5, also called survivin) is a novel
member of the inhibitor of apoptosis protein (IAP) family, which is
abundantly expressed in fetal tissues and in a variety of human
malignancies, but almost undetectable in normal or well-
differentiated adult tissues. [16] Overexpression of BIRC5 in
various cellular systems has been found to be uniformly associated
with inhibition of apoptosis, while the low expression of BIRC5
contributed to the enhanced spontaneous cell death. [17]
Consistently, various studies of Birc5 with conditional knockout
mice have shown phenotypes with exaggerated apoptosis, with or
without catastrophic mitotic defects. [18–21]
In a variety of human malignancies, the BIRC5 was frequently
observed to be markedly over-expressed. [22] Furthermore, the
BIRC5 expression has been positively correlated with poor
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16748prognosis of these cancers. [22] With regard to NPC, the elevated
expressions of BIRC5 were also observed in tumor cells and tumor
tissues compared with normal adjacent nasopharyngeal epithelium
and tissues. [23,24] For the outcome in NPC patients, the over-
expression of BIRC5 was significantly associated with advanced
clinical stage (III-IV), tumor stage (T3-4) and lymph node
metastasis (N1-3), and lower 5-year survival rate. [23,25]
Furthermore, the expression of BIRC5 in NPC tissues was
negatively correlated with the apoptosis index, which was equal to
the total number of apoptotic cells or bodies over total number of
tumor cells. [23,25] Additionally, knock-down of BIRC5 by RNA
interference in NPC cell lines (C666-1) has shown decreased
viability and increased apoptosis, suggesting a role for BIRC5 in
resistance to apoptosis in NPC. [24] The study in another NPC
cell line (tet-on LMP1 HNE2) found that the latent membrane
protein1 (LMP1) encoded by EBV could trigger the expression of
BIRC5, which then promoted cell proliferation and inhibited
apoptosis. [26] Taken together, these observations indicate that
the BIRC5 plays an important role in the NPC occurrence and
progression.
On the basis of above functional relevance of BIRC5 both in vitro
and in vivo in the pathogenesis of NPC, we hypothesize that the
BIRC5 may be an excellent biological candidate susceptibility gene
for the NPC. It is expected that the functional polymorphisms
within BIRC5 could result in genotype-dependent difference in
susceptibility to NPC.
Recently, a functional single nucleotide polymorphism (SNP),
i.e. -31C/G (rs9904341), in the promoter of BIRC5 gene was
identified. [27] This polymorphism is located at the cell cycle-
dependent elements (CDE) and cell cycle homology regions (CHR)
repressor binding site of the promoter. Several studies have shown
that the -31C/G polymorphism was associated with modified
binding affinity of the CDE/CHR repressor, changed activity of
the promoter, and subsequently resulted in different expression
levels of BIRC5 mRNA and protein in normal and cancer cells.
[27–29] The -31C allele was shown to have a significantly higher
transcriptional activity than the -31G allele, and carriers of the -
31CC genotype had an increased BIRC5 levels than those of the
GC and GG genotypes. [28–30] Therefore, it is hypothesized that
this functional SNP in the BIRC5 gene promoter may contribute to
individual’s tumor susceptibility. Indeed, several epidemiological
studies have shown -31C/G to be associated with the risk of lung,
[28] colorectal, [30] urothelial [31] and gastric cancer. [32] The
role of 231C/G in NPC, however, has never been specifically
investigated. In the present study, we examined whether the
functional polymorphism in the BIRC5 promoter, -31C/G, has




This study was performed with the approval of the Ethical
Committee of Beijing Institute of Radiation Medicine (Beijing,
China). At recruitment, written informed consent was obtained
from all participants involved in this study.
Study subjects
This case-control study included 855 incident patients with
NPC and 1036 control subjects. Among them, a total of 477
patients with NPC and 480 controls were previously recruited
between September 2003 and July 2005 at the Guangxi Cancer
Hospital (Nanning, China). [3,4] In this study, a further 378
patients with NPC were recruited from December 2005 to January
2008 at this hospital. All the 855 patients with NPC were newly
diagnosed and pathologically confirmed, and were unrelated
ethnic Chinese and residents in Nanning city and the surrounding
regions. The response rate for the case patients was 95%. Patients
that received chemotherapy or radiotherapy before surgery or had
other type of cancer were excluded from the present study. Tumor
staging was conducted according to the tumor-node-metastasis
(TNM) classification by the 1997 American Joint Committee on
Cancer (AJCC) system. [33] All TNM classifications were made by
senior pathologists of the hospital based on the postoperative
histopathologic examination. A further unrelated 556 cancer-free
individuals were recruited as controls. All the 1036 controls were
randomly selected from a community cancer screening program
for early detection of cancer conducted in the same regions during
the same time period as the NPC patients were collected. The
selection criteria for the controls included no individual history of
cancer and frequency matching to the cases on sex and age (65
years). The response rate for control subjects was 92%.
At recruitment, personal information on demographic factors,
medical history, and tobacco and alcohol use were collected via
structured questionnaire. As described previously, individuals were
considered smokers if they smoked up to 1 year before the date of
cancerdiagnosisforpatientswith NPCoruptothe date ofinterview
for controls. [3,4] Information was collected on the number of
cigarettes smoked per day, the age at which the individuals started
smoking,and the ageat which ex-smokers stoppedsmoking.Lighter
or heavier smokers were categorized by the approximated 50th
percentile pack-year value among controls [i.e., ,24 or $24 pack-
years; (cigarettes per day/20)6(years smoked)]. An alcohol drinker
was defined as someone who consumed alcoholic beverages at least
once per week for $6 months. The younger or older individuals
were categorized by the approximated mean age value among
controls [i.e., ,45 or $45 years].
Polymorphism genotyping
The -31C/G polymorphism (rs9904341) in the promoter of
BIRC5 gene was genotyped by TaqMan MGB technology (Assay
ID: C_25474467_10; Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s protocol. Briefly, polymerase
chain reaction (PCR) was performed in 5 mL volume with an
initial 2 min at 50uC and 10 min at 95uC, followed by 40 cycles of
15 s at 95uC and 1 min at 60uC. The ABI PRISM 7900HT Fast
Real-Time PCR System was used for the genotyping assay.
Sequence Detection Systems software (SDS 2.3, Applied Biosys-
tems) was used to automatically collect and analyze the data and to
generate the genotype calls. Genotyping was performed in a blind
manner so that the performers did not know the subjects’ case or
control status.
Case and control samples were distributed across each 384-well
plate at random, with 20 randomly selected duplicate samples and
4 water controls per plate. The TaqMan assay of duplicate
samples yielded a concordance rate of 100%. For further quality
control, a 15% masked, random sample of cases and controls was
tested by direct DNA sequencing and all results were 100%
concordance. The PCR and sequencing primers were 59-
GTTCTTTGAAAGCAGTCGAG-39 (Forward primer) and 59-
GCCAGTTCTTGAATGTAGAG-39 (Reverse primer). PCR was
performed with an initial denaturing step at 95uC for 3 min, 30
cycles of 94uC for 45 s, 57uC for 45 s, and 72uC for 1 min, and an
extension step at 72uC for 10 min.
Statistical analysis
Comparisons of sex, age, smoking and drinking status between
patients and controls were performed using the x
2 test. Differences
BIRC5 -31C/G and NPC Risk
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controls were analyzed by use of an unpaired t test. Genotype and
allele frequencies for the -31C/G polymorphism were determined
by gene counting. The significance of deviations from Hardy-
Weinberg equilibrium was tested using the random-permutation
procedure implemented in the Arlequin package (available at:
http://lgb.unige.ch/arlequin/). The association between the
genotypes and NPC risk was evaluated by multivariate logistic
regression analyses. The odds ratios (OR) and 95% confidence
intervals (CI) were adjusted for age, sex, smoking and drinking
status, smoking level, nationality and family history where
appropriate. Potential modification of the effect of -31C/G
genotypes on the risk and progression of NPC was assessed for
the above confounding factors by addition of interaction terms in
the logistic model and by separate analyses of subgroups of
individuals determined by these factors. A P value of ,0.05 was
used as the criterion of statistical significance, and all statistical
tests were two sided. These analyses were performed using SPSS
software (version 9.0; SPSS Inc., Chicago, IL).
Results
The selected characteristics of patients with NPC and control
subjects in Guangxi population are shown in Table S1. Overall,
the controls were comparable with patients with regard to sex and
tobacco and alcohol use. However, higher mean age was
presented in the cases compared with controls (P=0.0011, t test).
A significantly higher proportion of the cases were of Non-Han
nationality (P=2.5610
214) and positive for family history
(P=6.5610
25) compared with controls. An absolute majority of
the cases (97.0%) was classified as poorly differentiated squamous
cell carcinoma. When stratified according to the TNM system,
4.8%, 46.2%, 30.3% and 18.7% of the patients had stage I, II, III
and IV disease, respectively.
The genotyping results are shown in Table 1. This case-control
study included 855 incident patients with NPC and 1036 control
subjects. However, there were totally 26 samples that were
unsuccessfully genotyped, and the percentages of these samples
were similar in cases (1.3%) and controls (1.4%). Therefore, the
actual sample size was 844 (98.7%) and 1021 (98.6%) for cases and
controls, respectively. The observed genotype frequencies for the
-31C/G polymorphism conformed to the Hardy-Weinberg
equilibrium in both cases (P=0.20) and controls (P=0.85). The
frequencies of the CC, CG, and GG genotype among cases were
significantly different from those among controls (x
2=9.064,
P=0.011, degree of freedom =2), and this difference was mainly
caused by a higher frequency of the CC genotype among cases
compared with controls (28.0% versus 21.9%). Based on logistic
regression analysis with adjustment for age, sex, smoking and
drinking status, smoking level, nationality and family history, the
individuals carrying the -31CC genotype had a significantly
increased susceptibility to NPC occurrence compared with those
carrying the G allele (OR =1.40; 95% CI =1.13–1.73,
P=0.0020). When cases were limited to those with poorly
differentiated squamous cell carcinoma (n=829), the association
results were similar (OR =1.40; 95% CI =1.13–1.74,
P=0.0020).
To further examine the associations between the -31C/G
polymorphism and risk of NPC in the Guangxi population, we
stratified the cases and controls by age, sex, smoking and drinking
status, smoking level, nationality and family history (Table 2).
Although the increased risk of NPC associated with the BIRC5 -
31CC genotype seemed to be more pronounced in subjects who
were males, younger (,45 years), non-smokers, non-drinkers, Han
Chinese, and negative for family history, these differences could be
attributed to chance (all P$0.05, test for homogeneity). Specially,
we noted that although a significantly higher proportion of the
cases were of Non-Han nationality compared to the controls
(P=2.5610
214, Table 2), the frequencies of allele and genotype of
the -31C/G polymorphism were comparable between Han and
Non-Han groups, in both the cases and the controls (all P.0.05;
Table S2). Therefore, the case and control populations were
comparable in terms of their genetic ancestry in particular with
respect to the -31C/G polymorphism. The slight difference in
NPC risk between Han and Non-Han groups (Phomogeneity =0.50,
Table 2) further ruled out the influence of different ethnic ancestry
on our results. Taking together, the BIRC5 -31C/G polymorphism
was an independent risk factor of NPC occurrence in the Guangxi
population, with the potential confounding factors having no
significant modification effect on it.
The population attributable fraction (PAF) associated with this
genetic risk factor—the parameter that combines the strength of
the epidemiological influence (relative risk) and the frequency of
the genotype (population exposure rate)—can be estimated by the
formula PAF = f(RR-1)/[1+f(RR-1)], where f is the population
exposure rate, and RR is the relative risk (odds ratio). [34] The
PAF calculated by the RR (OR, 1.40 [95% CI, 1.13–1.73])
(Table 1) combined with the frequency of the CC genotype
(24.7%) (Table 1) indicates that 10.7% (95% CI, 3.9–18.0%) of the
elevation in the risk of developing NPC can be attributed to the
susceptibility effect of the -31CC genotype.
We also assessed the effect of the -31C/G genotype on severity
of NPC (as measured by tumor-node-metastasis staging system) in
the Guangxi population. However, the distributions of the -31C/
G genotypes were not statistically significantly different among the
subgroups with different clinical stage, or different T, N and M
classification of the cancer (Table 3).
In 855 NPC patients of the Guangxi population, the mean ages
at diagnosis (6 SD, years) were 45.53 (611.95) years for subjects
with the CC genotype, and 46.78 (611.94) years for those with the
CG or GG genotypes. Therefore, subjects with the at-risk CC
genotype were 1.25 years younger than those with the CG or GG
genotypes by age at diagnosis, although the difference was not
significant (P=0.17, t test).
Table 1. Risk of NPC associated with the BIRC5 -31C/G
polymorphism in the Guangxi population.
Genotype Cases, n (%) Controls, n (%)
GG 205 (24.3) 273 (26.7)
CG 403 (47.7) 524 (51.3)
CC 236 (28.0) 224 (22.0)
OR (95% CI)
CC vs. GG 1.41 (1.09–1.82)
CC vs. CG 1.39 (1.11–1.75)
CC vs. GG + CG 1.40 (1.13–1.73)
P value
CC vs. GG 0.0093
CC vs. CG 0.0040
CC vs. GG + CG 0.0020
Due to genotyping failure, the actual sample size was 844 and 1021 for the
cases and controls, respectively. OR, odds ratio; CI, confidence interval.
The ORs and P values were adjusted for age, sex, smoking and drinking status,
smoking level, nationality and family history.
doi:10.1371/journal.pone.0016748.t001
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In this study, we assessed the associations of the functional
polymorphism -31C/G in the promoter of BIRC5 gene with the
risk of occurrence and progression of NPC in the Guangxi
population. No genetic association was found between this
polymorphism and the progression of NPC. However, this
polymorphism was significantly associated with the onset of
NPC, with the individuals who carried the -31 CC genotype
having an increased risk of occurrence of NPC, compared to those
with the CG or GG genotypes. Subjects with the at-risk CC
genotype tended to be younger than those with the CG or GG
genotypes by age at diagnosis further supported a role of the
BIRC5 -31C/G polymorphism in the etiology of NPC. To our best
knowledge, this is the first report of the genetic association between
the BIRC5 and NPC risk, confirming the initial hypothesis that the
BIRC5 may play a role in the pathogenesis of this malignancy.
The genetic association between BIRC5 -31C/G and the onset
of NPC is biologically plausible. BIRC5 is a member of IAP family
and plays a key role in inhibiting apoptosis and promoting cell
proliferation. [16,35] The anti-apoptotic function of BIRC5 has
been demonstrated both in vitro and in vivo. [17,36] The
mechanisms by which BIRC5 inhibits apoptosis are complicated,
including regulation of the expression and function of BIRC5 to
provide a different cell-survival threshold, physical interactions
between BIRC5 and other molecules to exert anti-apoptotic
effects, and compartmentalization of BIRC5 in mitochondria and
release of the protein in the cytosol in response to the cell death
stimuli. [22] In NPC, several studies have demonstrated that both
mRNA and protein levels of BIRC5 were elevated in cancer
tissues of NPC when compared with normal nasopharyngeal
epithelium tissues. [23,24] Furthermore, the expression of BIRC5
in NPC tissues was found to be negatively correlated with
apoptosis index, [23,25] and, the knockdown of BIRC5 by RNA
interference in NPC cell line showed decreased viability and
increased apoptosis. [24]
Given the role of BIRC5 in the development of NPC, together
with the earlier described functional relevance of -31C/G in
modulation of BIRC5 expression, one might expect that
individuals who carry the -31 CC genotypes, and thus have
increased expression of BIRC5 and subsequently increased anti-
apoptotic function, may be at a higher susceptibility to developing
NPC. If carrying the -31 CC is regarded as a risk factor for the
development of NPC, then the PAF calculated by the RR
combined with the frequency of CC genotype indicates that 10.7%
(95% CI, 3.9–18.0%) of elevation in the risk of developing NPC
can be attributed to the susceptible effect of the -31CC genotype.
At this stage, the BIRC5 -31C/G polymorphism is unlikely to be
appropriate for risk prediction testing. However, with more
susceptibility loci being identified (e.g., by genome-wide associa-
tion studies), and interaction effects among such loci together with
other NPC risk factors taken into account, the prediction of NPC
occurrence may become more accurate and clinically usable.
It has been reported that BIRC5 was markedly over-expressed
in a broad range of human cancers. However, up to date, the
BIRC5 -31C/G polymorphism was only reported to be associated
Table 2. Risk of NPC associated with the BIRC5 -31C/G polymorphism by potential risk factors in the Guangxi population.
Category CC
1 CG + GG





Male 168/153 443/583 1.45 (1.13–1.87) 0.0042
Female 68/71 165/214 1.20 (0.81–1.79) 0.36
Age 0.61
$45 126/113 331/394 1.32 (0.98–1.77) 0.067
,45 110/111 277/403 1.46 (1.07–1.98) 0.017
Smoking status 0.19
Nonsmoker 166/146 424/566 1.56 (1.20–2.02) 0.0010
Smoker 70/78 184/231 1.10 (0.75–1.62) 0.64
Smoking level (pack-years) 0.72
$24 30/27 75/96 1.48 (0.80–2.74) 0.21
,24 40/51 109/135 0.92 (0.56–1.51) 0.73
Drinking status 0.78
Nondrinker 160/155 432/566 1.37 (1.06–1.77) 0.015
Drinker 76/69 176/231 1.43 (0.97–2.12) 0.075
Nationality 0.50
Han 173/199 448/692 1.37 (1.08–1.74) 0.010
Non-Han 63/25 160/105 1.68 (0.95–2.98) 0.077
First-family history 0.49
Positive 16/9 38/20 1.66 (0.51–5.41) 0.40
Negative 220/215 570/777 1.41 (1.13–1.75) 0.0022
Due to genotyping failure, the actual sample size was 844 and 1021 for the cases and controls, respectively. OR, odds ratio; CI, confidence interval.
1Number of genotype in cases/number of genotype in controls.
2The ORs and P values were calculated by logistic regression with the CG + GG genotype as the reference group and adjusted for age, sex, smoking and drinking status,
smoking level, nationality and family history where appropriate within the strata.
3For difference in ORs within each stratum.
doi:10.1371/journal.pone.0016748.t002
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colorectal cancer, [30] gastric cancer [32] and NPC in the present
study. The magnitude of NPC risk found with the CC genotype in
the present study (OR =1.40, 95%CI: 1.13–1.73) was similar to
the risk observed for lung cancer (OR =1.35, 95%CI: 1.04–1.75),
but less than the risks observed for sporadic colorectal cancer (OR
=2.68, 95%CI: 1.77–4.07), urothelial carcinoma (OR =4.0,
95%CI: 2.3–7.2), and gastric carcinoma (OR =4.83, 95%CI:
2.91–8.03) [28,30–32]. However, given that the sample size of the
later three studies were relatively small, the ORs in these studies
might not indicate the real magnitudes of risk. Therefore, whether
or not the magnitudes of risk reflect different roles of the -31C/G
in different cancers warrants further investigation.
Furthermore, we have analyzed and compared the BIRC5 -
31C/G polymorphism in populations from Taiwan (one of the
regions with high NPC incidence), Hubei province (Central China)
and Jiangsu province (Eastern China) based on available published
data [31,32,37], and also compared the SNP with 11 populations
from HapMap to see how different they are from our own study.
As shown in Table S1, the allele and genotype frequencies of the
BIRC5 -31C/G polymorphism in our controls were similar to
those of Mexicans and some populations of Chinese and African
descent, but significantly different from those of other populations
including Taiwan (x
2 test). However, frequencies of the at-risk CC
genotype were similar between controls from Taiwan and those in
this study. It remains to be determined whether these differences
between ethnic groups influence susceptibility to NPC.
Previous studies have reported that the BIRC5 -31C/G
polymorphism was associated with invasiveness or metastasis of
some types of cancer. [31,37] In NPC patients, the over-expression
of BIRC5 has been shown to be extensively related to the poor
outcome, including advanced clinical stage, tumor stage and
lymph node metastasis, and lower 5-year survival. [23,25] In the
present study, however, we did not found any significant
associations between the -31C/G polymorphism and the patho-
logical stages of NPC. These findings may be due to the different
molecular mechanisms of carcinogenesis among cancers and/or
different ethnicities of study populations. In addition, these
findings could be the result of the limited sample size and
statistical power of our study. For example, this study has merely a
power of 62.6% (I + II vs. III + IV), 56.1% (T1 + T2 vs. T3 + T4),
56.3% (N0 + N1 vs. N2 + N3) and 12.6% (M0 vs. M1) to detect an
OR of 1.40 for carriers of the CC genotype relative to the carriers
of the CG + GG genotypes. Therefore, we urge that the role of the
-31C/G in the progression of NPC be investigated in additional
studies with larger sample sizes.
In reviewing the results of this study, one must also keep two
potential limits in mind. First, as a hospital-based study, our NPC
cases were recruited from the hospital, while the controls were
selected from the community population. Therefore, the inherent
selection bias cannot be completely excluded. Well-designed and
carefully executed multi-centre studies, with enrollment of large
number of subjects, are warranted to draw conclusions which are
more convincing and generalizable. Secondly, although the highly
significant association between BIRC5 and susceptibility to NPC is
derived from a biologically based a priori hypothesis, our initial
findings should be independently verified in other populations with
a high incidence rate of NPC, such as other southern Chinese,
Singaporeans, and Taiwanese. Therefore, any association report-
ed in the present study should be interpreted with great caution,
because without rigorous replication we cannot rule out the
possibility that these findings are only due to chance.
In addition to BIRC5, many other candidate genes involving in
different steps of carcinogenesis have also been implicated in NPC
susceptibility. Further studies are needed to systematically verify
these susceptibility genes, investigate the interactions between
genetic and non-genetic risk factors, including dietary habit (e.g.
salt fish) and EBV infection among others, and assess their
contributions to the endemics of NPC among Chinese.
In conclusion, our results reveal an association for the first time
between the functional polymorphism -31C/G in the promoter of
BIRC5 and susceptibility to NPC, and, the -31CC genotype, which
are genetically predisposed to produce an increased expression
level of BIRC5, seem to be a genetic risk factor for the NPC risk in
a Chinese population. If confirmed by other studies, knowledge of
genetic factors contributing to the pathogenesis of the NPC as
presented here may have implications for the cancer screening and
treatment of this disorder in the future.
Supporting Information
Table S1 Of the 855 cases and 1036 controls involved in the
present study, some were derived from our previous study [3,4]
and others were newly recruited. In cases, non-Han includes
Zhuang (n=211), Dong (n=1), Hui (n=1), Miao (n=1), Mulao
(n=3) and Yao (n=10) nationality; in controls, non-Han includes
Zhuang (n=132) nationality. Other histological types include
vesicular nucleus cell carcinoma (n=14), poorly differentiated
adenocarcinoma (n=4), and moderate differentiated squamous
cell carcinoma (n=5); and undifferentiated cancer (n=3).
Comparisons of sex, age, smoker, smoking level, and drinker
distributions between patients and controls were performed by use
of the x
2 test. Differences of mean age and mean smoking level
between patients and controls were analyzed by use of an unpaired
t test. SD, standard deviation.
(DOC)
Table 3. Distributions of genotypes of the BIRC5 -31C/G
polymorphism among the subgroups with different severity










Clinical 0.946 0.372 3
I 12 (29.3) 29 (70.7)
II 113 (28.8) 279 (71.2)
III 68 (26.9) 185 (73.1)
IV 43 (27.2) 115 (72.8)
T 0.469 2.536 3
T1 45 (26.5) 125 (73.5)
T2 121 (29.0) 296 (71.0)
T3 42 (24.4) 130 (75.6)
T4 28 (32.9) 57 (67.1)
N 0.918 0.502 3
N0 50 (28.6) 125 (71.4)
N1 116 (28.3) 294 (71.7)
N2 47 (26.0) 134 (74.0)
N3 23 (29.5) 55 (70.5)
M 0.191 1.709 1
M0 233 (28.3) 591 (71.7)
M1 3 (15.0) 17 (85.0)
Due to genotyping failure, the actual sample size was 844 cases.
doi:10.1371/journal.pone.0016748.t003
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were derived from previously published studies [31,32,37]. ASW,
African ancestry in southwest USA; YRI, Yoruba in Ibadan,
Nigeria; LWK, Luhya in Webuye, Kenya; MKK, Maasai in
Kinyawa, Kenya; CHB, Chinese Han in Beijing, China; CHD,
Chinese in Metropolitan Denver, Colorado; GIH, Gujarati
Indians in Houston, Texas; JPT, Japanese in Tokyo, Japan;
CEU, Utah residents with northern and western European
ancestry from the CEPH collection; TSI, Toscani in Italia;
MEX, Mexican ancestry in Los Angeles, California.
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